Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2016  |  Volume : 12  |  Issue : 5  |  Page : 23-26

Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis


1 Department of Hematology, The 6th Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, P.R. China
2 Department of Clinical Laboratory, The 6th Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, P.R. China

Correspondence Address:
Peng Wang
Department of Clinical laboratory, The 6th Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province
P.R. China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.191623

Rights and Permissions

Objective: The aim of this study was to evaluate the clinical efficacy and safety of high-dose imatinib (IM) for chronic myeloid leukemia (CML) patients by pooled published studies. Methods: Through searching the databases of PubMed, EMBASE, ASCO, ESMO, CNKI, and Wanfang, we collected open published clinical controlled trials-related high-dose IM treatment of CML. The pooled complete cytogenetic response (CCyR) and hematologic toxicities were calculated by the statistical software. Results: Seven studies were included in this study with 1137 cases received high-dose IM treatment and 958 cases received regular-dose IM treatment. The pooled results showed that patients received high-dose IM had higher CCyR compared with regular-dose with the odds ratio (OR) of 1.75 (95% confidence interval [95% CI]: 1.44–2.1, P < 0.05) and 1.58 (95% CI: 1.38–1.81, P < 0.05) in 6 and 12 months. However, the hematologic toxicities risk of neutropenia (OR = 1.76, 95% CI: 1.22–2.54) and thrombopenia (OR = 1.88, 95% CI: 1.42–2.50) were much higher in the high-dose group. Conclusion: High-dose IM for CML treatment was superior to standard-dose IM in the aspects of CCyR, but the risk of developing neutropenia and thrombopenia was much higher.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2117    
    Printed21    
    Emailed0    
    PDF Downloaded193    
    Comments [Add]    

Recommend this journal